Hers is a complete women's health platform covering weight loss, hair, skin, and mental health. Shed is a dedicated GLP-1 weight loss platform with a 10% guarantee. For women focused purely on weight loss, this comparison helps determine which is the better investment.
Platform Overview
Hers is a women's health telehealth platform that has expanded significantly into GLP-1 weight loss treatment, leveraging a Novo Nordisk partnership that provides access to branded semaglutide (Wegovy) in addition to compounded options. Founded in 2018 as the women's counterpart to Hims, Hers charges $199-$299 per month for its weight loss programs and has built a large, engaged user base among women seeking holistic health management including mental health, skincare, and sexual health alongside weight loss. Hers' women-centric approach means its clinical and coaching frameworks are tailored to female-specific considerations including hormonal influences on weight, PCOS, and menopause-related weight gain. The FDA has documented hormonal and metabolic factors that affect GLP-1 treatment response in women.
Shed is a gender-neutral GLP-1 weight loss specialist offering semaglutide and tirzepatide programs at $199-$499 per month. The platform's clinical protocols are designed to optimize weight loss outcomes for all patients, with its 10% body weight loss guarantee serving as the central accountability feature. Shed's focus is narrower than Hers - exclusively weight loss rather than broader women's health - but this singular focus allows deeper specialization in its treatment protocols and coaching infrastructure. The
CDC's weight management guidelines note that tailored program support improves adherence, and Shed's specialist model is designed around this principle.
Pricing Comparison
Hers offers weight loss programs at $199-$299 per month, making it one of the more affordable GLP-1 telehealth options in the market. The Novo Nordisk partnership means Hers can provide access to branded Wegovy for patients who qualify and prefer a brand-name option, though compounded semaglutide is also available at the lower price points. Hers does not advertise a weight loss guarantee, so patients who progress slowly bear the full financial risk. The platform's lower pricing reflects partial offset from its broader women's health product revenue, allowing it to keep weight loss program costs competitive.
NIH treatment cost research highlights affordability as a key adherence factor.
Shed's pricing of $199-$499 per month is comparable to Hers at the entry level, with higher-tier plans reflecting more intensive support options. The key financial differentiator is Shed's 10% weight loss guarantee, which provides outcome assurance that Hers does not match. For women who have tried multiple weight loss approaches without sustained success, the guarantee reduces the perceived risk of investing in another program. Shed's pricing is transparent, and the guarantee terms define what happens if the program target is not achieved - a level of financial accountability that is rare in the GLP-1 telehealth space.
Medication Options and Quality
Hers' Novo Nordisk partnership is a significant differentiator, providing access to FDA-approved branded Wegovy (semaglutide injection) in addition to compounded semaglutide alternatives. Branded GLP-1 medications undergo more stringent quality controls than compounded versions, which can be important to patients concerned about compound pharmacy variability. Hers also offers tirzepatide through compounding channels. The platform's women's health focus means providers are particularly attuned to interactions between GLP-1 therapy and hormonal health, contraceptive use, and reproductive considerations.
NEJM clinical data confirms semaglutide's efficacy across diverse patient populations including women with varied hormonal profiles.
Shed provides both semaglutide and tirzepatide through licensed compounding pharmacies, with clinical prescribing guided by a thorough intake evaluation. The platform's medication options cover the full spectrum of current GLP-1 weight loss treatment, and tirzepatide's superior efficacy - producing 20%+ average weight loss in trials per
NEJM - is available to qualifying patients. Shed does not have a branded medication partnership like Hers' Novo Nordisk arrangement, but its compounded options are sourced through FDA-registered pharmacies with appropriate quality controls.
Medical Team and Support
Hers' medical team includes providers with specific training in women's health, meaning GLP-1 treatment is delivered within a broader understanding of female physiology. This is particularly valuable for women whose weight challenges intersect with hormonal conditions like PCOS, hypothyroidism, or perimenopause. The platform provides messaging access to clinical staff and has support resources tailored to women's experience of weight loss, including content addressing emotional eating, body image, and the distinct hormonal factors that complicate weight management for many women. Research published in JAMA confirms that gender-responsive clinical models improve treatment engagement.
Shed's medical support includes licensed physicians and nurse practitioners who oversee all prescription decisions, alongside dedicated weight loss coaches who are the primary ongoing contact for most patients. The coaching model focuses on behavioral adherence, progress monitoring, and motivational support throughout the program. While Shed's providers serve all genders rather than specializing in women's health, the weight loss coaching infrastructure is highly developed. The
American Association of Clinical Endocrinology recommends behavioral coaching as a standard component of GLP-1 obesity treatment, and Shed builds this directly into its program design.
Weight Loss Approach and Programs
Hers takes a holistic women's health approach to weight loss, recognizing that for many women, weight management is deeply intertwined with hormonal health, mental health, and lifestyle factors that are addressed through other Hers programs. The platform's weight loss protocols include GLP-1 pharmacotherapy, nutritional guidance, and lifestyle recommendations, with the clinical team attuned to female-specific factors affecting metabolism and body composition. Hers' integration of mental health support is a genuine advantage, as emotional and psychological factors significantly influence weight loss success.
Research in Obesity journal documents the bidirectional relationship between mental health and weight management outcomes.
Shed's weight loss approach is pharmacologically anchored in GLP-1 treatment, complemented by dedicated coaching that drives toward the 10% body weight guarantee. The program structure is designed for efficient progression toward the guaranteed threshold, with regular check-ins and dose adjustments calibrated to patient response. This focused model is particularly effective for patients who want clear milestones and outcome accountability rather than a holistic health platform. Shed's guarantee creates a performance standard that motivates both the clinical team and the patient to optimize every element of the program.
User Experience and Satisfaction
Hers users report high satisfaction with the platform's women-specific approach and the quality of its content and community resources. The platform's app experience is polished, and patients managing multiple health conditions through Hers find the integrated dashboard convenient. Women who have felt dismissed by traditional healthcare providers regarding weight concerns report that Hers' empathetic, women-first approach is a meaningful differentiator. Some users note that the weight loss program could offer more intensive coaching depth, and those who want very high-touch support sometimes feel the interaction frequency is lighter than they expected at the price point.
Shed users highlight the guarantee as a major satisfaction driver - knowing there is a committed outcome target changes the psychological experience of the program. Coaches are described as proactive and goal-focused, which suits patients who want accountability rather than passive support. The platform's weight loss-specific design means all features, tracking tools, and progress metrics are oriented around the weight loss goal rather than general health management. The
NIH's GLP-1 adherence research shows that structured accountability significantly improves long-term medication adherence and outcomes.
How We Tested Hers vs Shed
Our Comparison Methodology
This comparison is based on complete analysis supplemented by peer-reviewed research on weight loss treatment.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication information (FDA Wegovy Label), obesity treatment guidelines from the American Association of Clinical Endocrinology, and clinical efficacy data from The New England Journal of Medicine.
Research Foundation: We analyzed peer-reviewed studies including GLP-1 medication efficacy from Obesity and behavioral support impact from JAMA.
Pricing Analysis: All pricing reflects published rates as of March 2026, verified through official platform websites.
Service Verification: Platform capabilities, provider credentials, and service quality were evaluated through detailed review of service offerings.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Hers vs Shed
Choose Hers if: You are a woman who wants weight loss treatment integrated with broader women's health support, including hormonal health awareness, mental health resources, and access to branded Wegovy through a Novo Nordisk partnership. Hers is particularly strong for women managing PCOS, perimenopause, or other hormonal factors that intersect with weight.
Choose Shed if: Weight loss is your primary goal and you want outcome accountability through a 10% body weight guarantee. Shed's specialist model and dedicated coaching infrastructure are designed exclusively around producing and sustaining weight loss results, making it the stronger choice for outcome-focused patients.
Bottom line: Hers and Shed serve somewhat different patient profiles. Hers excels as a holistic women's health platform with strong GLP-1 capabilities, while Shed excels as a pure-play weight loss specialist with guaranteed outcomes. Women who want the most complete women's health platform should choose Hers; women who want the strongest outcome accountability for weight loss specifically should choose Shed.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
